# Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

> **NCT01652729** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 365 (actual)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Exenatide once weekly suspension
- **DRUG:** Sitagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01652729
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2015-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652729, "Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT01652729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*